TAFINLAR: payments to doctors
Payments that named TAFINLAR as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.4M
- Providers
- 4,794
- Transactions
- 15,232
- Average per transaction
- $93
The per-transaction average — $93 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,794 providers the average total is $296, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novartis | $1,415,991 | 99.6% |
| Novartis Pharma AG | $4,974 | 0.4% |